CNL and aCML should be considered as a single entity based on molecular profiles and outcomesGonzalo Carreño‐Tarragona, Nicholas C.P. Cross, Alberto Álvarez‐Larrán et al.|Blood Advances|2023Cited by 32
Occlutech percutaneous patent foramen ovale closure: Safety and efficacy registry (OPPOSE)David Hildick‐Smith, Lindsay Morrison, Mark Monaghan et al.|International Journal of Cardiology|2017Cited by 19